GlassScriptPhysician profile
Lucy Rivilis
NPI 1225471568
$6,832.13
in general payments reported to CMS, 2019-2025
46 companies · $1,137 in 2025
The $1,137 reported for 2025 was more than what 87% of Adult Health (Nurse Practitioner) providers received nationally (typical 2025 total: $182).
See the full distribution for Adult Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,829 · 2022: $1,102 · 2023: $1,464 · 2024: $1,301 · 2025: $1,137.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,901.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,901.19 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,239.85 | 2021-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,006.03 | 2021-2025 | Xifaxan, Trulance, Plenvu |
| Astrazeneca Pharmaceuticals LP | $621.12 | 2021-2025 | Breztri, Airsupra, Farxiga |
| Novo Nordisk INC | $523.49 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $486.05 | 2021-2025 | Mounjaro, Jardiance, Zepbound |
| Glaxosmithkline, LLC. | $369.61 | 2021-2023 | Trelegy Ellipta, Arexvy |
| Bayer Healthcare Pharmaceuticals INC. | $241.06 | 2022-2025 | |
| Phathom Pharmaceuticals, INC. | $226.79 | 2024-2025 | Voquezna |
| Indivior INC. | $143.03 | 2021-2022 | |
| Gilead Sciences, INC. | $125.80 | 2023-2025 | |
| Amgen INC. | $115.63 | 2023-2025 | Repatha, Otezla, Repatha |
| Idorsia Pharmaceuticals US INC | $102.76 | 2023-2024 | Quviviq |
| Orexo US, INC. | $97.04 | 2021 | |
| Abbott Laboratories | $96.63 | 2021-2023 | Freestyle Libre 3 |
| Redhill Biopharma INC. | $92.42 | 2021-2022 |
Show all 46 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lucy Rivilis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.